Exploring The Potential of CLSTN3 as A Drug Target and Biomarker

Target Name: CLSTN3

NCBI ID: G9746

CLSTN3

Exploring The Potential of CLSTN3 as A Drug Target and Biomarker

CLSTN3 (calbindin-3) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a calcium-binding protein that is involved in a variety of physiological processes in the body, including bone development and maintenance, muscle contractions, and nerve function.

Recent studies have suggested that CLSTN3 may have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential of CLSTN3 as a drug target and biomarker, as well as its current status in research.

The Potential of CLSTN3 as a Drug Target

CLSTN3 has been identified as a potential drug target due to its involvement in a variety of signaling pathways that are involved in various diseases. For example, CLSTN3 has been shown to be involved in the regulation of cell proliferation, differentiation, and survival. It has also been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

One of the potential benefits of targeting CLSTN3 as a drug target is its potential to treat a variety of diseases that are currently un treatable or have limited treatment options. For example, CLSTN3 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By targeting CLSTN3, researchers may be able to develop new treatments for these diseases that can slow or stop the progression of the disease.

Another potential benefit of targeting CLSTN3 as a drug target is its potential to improve the overall quality of life for patients. For example, CLSTN3 has been shown to be involved in the regulation of pain perception and neuroinflammation, which can have a significant impact on a patient's quality of life. By targeting CLSTN3, researchers may be able to develop new treatments for pain perception and neuroinflammation that can improve a patient's overall quality of life.

The Potential of CLSTN3 as a Biomarker

CLSTN3 has also been identified as a potential biomarker for a variety of diseases, including cancer and neurodegenerative diseases. This is because CLSTN3 is expressed in a variety of tissues and has been shown to be involved in the regulation of various physiological processes in the body.

One of the potential benefits of using CLSTN3 as a biomarker is its potential to detect the early stages of disease. For example, CLSTN3 has been shown to be expressed in a variety of tissues, including the pancreas, brain, and gastrointestinal tract. This suggests that CLSTN3 may be a useful biomarker for detecting the early stages of diseases that affect these tissues, such as cancer and neurodegenerative diseases.

Another potential benefit of using CLSTN3 as a biomarker is its potential to monitor the effectiveness of existing treatments. For example, CLSTN3 has been shown to be involved in the regulation of cell proliferation and survival, which can be used to monitor the effectiveness of existing treatments for cancer and neurodegenerative diseases.

The Current State of Research on CLSTN3

CLSTN3 is an increasingly popular drug target and biomarker due to its involvement in various physiological processes in the body. Currently, there are several ongoing research studies focused on targeting CLSTN3 as a drug target and biomarker.

One of the most significant ongoing research studies is the use of CLSTN3 as a drug target for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Researchers are using a variety of techniques, including RNA interference, to

Protein Name: Calsyntenin 3

Functions: Postsynaptic adhesion molecule that binds to presynaptic neurexins to mediate both excitatory and inhibitory synapse formation (PubMed:25352602). Promotes synapse development by acting as a cell adhesion molecule at the postsynaptic membrane, which associates with both neurexin-alpha and neurexin-beta proteins at the presynaptic membrane (PubMed:25352602). Regulates the balance between excitatory and inhibitory synapses by inhibiting formation of excitatory parallel-fiber synapses and promoting formation of inhibitory synapses in the same neuron (By similarity). May also be involved in ascorbate (vitamin C) uptake via its interaction with SLC23A2/SVCT2 (PubMed:34673103). Complex formation with APBA2 and APP, stabilizes APP metabolism and enhances APBA2-mediated suppression of beta-APP40 secretion, due to the retardation of intracellular APP maturation (PubMed:12972431) (Probable)

The "CLSTN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLSTN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets